After Abbott Deal Collapses, GE Unlikely To Seek Similar-Sized Dx Buy This Year

Jul 18, 2007

This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.

A couple of days after announcing that has pulled out of its planned $8.1 billion acquisition of two of Abbott’s diagnostics divisions, GE officials suggested during a conference call that it was highly unlikely that the firm would make any acquisitions this year costing more than $2 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Synthetic Genomics Sued for Gender Discrimination

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Football Team's DNA Day Postponed

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

This Week in Cell

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Main menu